XENE
Xenon Pharmaceuticals Inc
36.40$
-0.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.0% | -95.7% | -6.3% | +1,660.0% | -93.9% | +0.0% | -100.0% | – | – | -100.0% | – | – | -4.9% | +112.6% | +89.1% | -51.0% | -21.4% | -15.4% | -49.1% | +266.3% | -54.0% | +134.6% | -93.9% | -75.4% | -93.4% | -100.0% | – | – | – | -100.0% | – | – | – | +198.1% | -100.0% | – | – | – | – | – | |
| – | -98.4% | +73,687.5% | +3.5% | +17.3% | -10.7% | -13.0% | -2.7% | +10.8% | +6.7% | +42.7% | -10.2% | +18.8% | +20.5% | +0.3% | -9.1% | +21.7% | +14.7% | +9.0% | +12.7% | +2.8% | +15.9% | -11.5% | +14.4% | +32.9% | -98.3% | -31.3% | +70.1% | +188.0% | -50.9% | -29.6% | +10.0% | +1.5% | -5.4% | – | – | +12,092.1% | -99.2% | -3.9% | – | – | |
| – | – | -1,699.7% | – | – | – | – | – | – | – | – | – | – | – | +112.6% | +89.1% | -51.0% | -249.8% | – | – | – | – | – | – | – | – | – | – | – | – | -113.2% | – | – | – | +496.2% | -108.4% | – | – | – | – | – | |
| – | -26.3% | +34.3% | +3.5% | +17.3% | -10.7% | -12.8% | -3.1% | +15.4% | +2.7% | +42.6% | -10.2% | +18.8% | +20.5% | +0.3% | -9.1% | +21.7% | +14.7% | +9.0% | +12.7% | +2.8% | +15.9% | -11.5% | +14.4% | +32.9% | +18.3% | +13.5% | +11.4% | -2.6% | -4.2% | +7.7% | +12.3% | +14.6% | +4.4% | +2.9% | +22.5% | +2.8% | +13.8% | +0.9% | +12.1% | – | |
| – | -18.9% | +45.6% | -14.3% | -3.1% | -4.2% | +34.0% | -2.7% | -11.0% | +4.6% | +29.2% | -12.0% | +17.0% | +17.6% | +4.6% | -0.3% | -3.1% | -3.2% | +32.3% | +54.3% | -23.8% | +38.4% | +1.3% | +28.5% | +1.4% | -3.7% | +12.2% | +21.5% | +10.5% | -1.4% | +17.2% | +31.2% | -13.9% | +7.8% | +5.7% | +1.1% | +0.2% | +14.4% | +7.9% | +0.5% | – | |
| – | -24.6% | +37.1% | -1.2% | +12.6% | -9.4% | -3.1% | -3.0% | +7.8% | +3.1% | +39.4% | -10.6% | +18.4% | +19.9% | +1.2% | -7.2% | +15.8% | -80.9% | +32.3% | +54.3% | -23.8% | +38.4% | +1.3% | +28.5% | +1.4% | +390.8% | +13.2% | +13.4% | +0.1% | -3.6% | +8.8% | +18.2% | +6.6% | +5.2% | +3.6% | +16.6% | -79.4% | +466.1% | +2.9% | +9.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -100.0% | – | – | – | -88.6% | +25.8% | +239.0% | -47.3% | +0.3% | +2.0% | -0.5% | -4.1% | -5.2% | -53.3% | -100.0% | – | -100.0% | – | – | -100.0% | – | +601.6% | +18.7% | +12.0% | +121.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -228.3% | – | – | – | – | – | -221.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +41.5% | -186.7% | – | – | – | +1,035.7% | +25.8% | +239.0% | -47.3% | -89.6% | -178.4% | – | -820.0% | – | – | – | – | -585.7% | – | – | – | -181.4% | – | -100.9% | – | -74.5% | -175.9% | – | – | – | -180.8% | – | – | – | -246.6% | – | -20.5% | -577.9% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -8,405.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.